Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML
- 27 January 2006
- journal article
- review article
- Published by Taylor & Francis in Emerging Therapeutic Targets
- Vol. 10 (1) , 51-68
- https://doi.org/10.1517/14728222.10.1.51
Abstract
(2006). Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert Opinion on Therapeutic Targets: Vol. 10, No. 1, pp. 51-68. doi: 10.1517/14728222.10.1.51Keywords
This publication has 122 references indexed in Scilit:
- CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTSAnnual Review of Pharmacology and Toxicology, 2005
- Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosisCell Death & Differentiation, 2005
- A microRNA polycistron as a potential human oncogeneNature, 2005
- Class II Histone Deacetylases: from Sequence to Function, Regulation, and Clinical ImplicationMolecular and Cellular Biology, 2005
- Calorie restriction, SIRT1 and metabolism: understanding longevityNature Reviews Molecular Cell Biology, 2005
- Caspase-dependent, geldanamycin-enhanced cleavage of co-chaperone p23 in leukemic apoptosisLeukemia, 2004
- Post-translational modification of p53 in tumorigenesisNature Reviews Cancer, 2004
- Discrete Roles for Histone Acetylation in Human T Helper 1 Cell-specific Gene ExpressionPublished by Elsevier ,2004
- Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1Nature Genetics, 2004
- Transcription Factor GATA-2 Gene Is Located Near 3q21 Breakpoints in Myeloid LeukemiaBiochemical and Biophysical Research Communications, 2000